
    
      Evaluation of efficacy and safety of 45 days of rivaroxaban 10 mg vs. fondaparinux 2.5 mg in
      the treatment of superficial vein thrombosis of risk patients for major VTE complications to
      prove non-inferiority of oral rivaroxaban treatment
    
  